The Use of Biosimilars in the Middle East: Review Article

  • Nazar AbdulLateef Jassim
  • Yasameen Abbas Humadi
Biosimilars (E Mysler, Section Editor)
Part of the following topical collections:
  1. Topical Collection on Biosimilars


Purpose of Review

Biosimilars are of growing importance worldwide, and many leading countries are introducing them in their health care systems and are using them in many fields of medicine owing to their low price tags in comparison with the brands and to their similarities in terms of function and side effects. So we cannot look past them and continue to rely on the innovator drugs since many had proven their efficacies in number of researches and Trials, not to mention the burden that many diseases pose on the budgets of the third world countries making using a lower priced alternatives a much appealing choice for the decision makers. Many fields of medicine in Iraq have experiences with the use of these agents over the past few years like the use of vaccines, insulin, and Growth factors, but their use in rheumatic disorders is still unfamiliar in our country. Our main aim doing this Review was to go through the written data on use of biosimilars in nearby countries and regions and draw some information regarding Types used, Terms of use and market release, different related legislations- if any-, patient’s selection criteria for their use in case of the presence of Brands, and examine the systems of successful pharmacovigilance, to guide us in producing our own guidance for perfect utilization of the newly arriving drugs.


Overall, there were 21 separate articles in which the biosimilars were mentioned as integral parts of the reviews and main body of subject. Even these reports have deficiencies in descriptions of types of drugs, Prices, Patient selection strategies and Efficacy studies.


The biosimilar use is still considered a new encounter in the Middle Eastern areas, many countries have never had any experience with their use, With Very little published data in this regard.


We advise the researchers and workers in this Region to pay more attention to documentation and publication of their works and experiences.


Biosimilars Intended copies Middle East Arab reigns Guidelines Pharmacovigilance 


Compliance with Ethical Standards

Conflict of Interest

The authors declare that they have no conflict of interest.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.


Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. 1.••
    Farhat F., Othman A., el Karak F., Kattan J. Review and results of a survey about biosimilars prescription and challenges in the Middle East and North Africa region. SpringerPlus. Nature publishing group, 2016;5:2113. This article is one of the very few published papers that reflects the Arabic physicians’ knowledge about biosimilars in different specialities.
  2. 2.
    Labeling for biosimilar products/guidance for industry, March 2016. [Online]. Available:
  3. 3.
    U.S. Food and Drug Adminstration, 2000. [Online]. Available:
  4. 4.
  5. 5.
    Boehm G, Yao L, Hanab L, Zhen Q. Development of the generic drug industry in the US after the Hatch-Waxman Act of 1984. Acta Pharm Sin B. 2013;3:297–311.CrossRefGoogle Scholar
  6. 6.
    Guideline on similar biological medicinal products, 23 October 2014. [Online]. Available:
  7. 7.
    Informa Life Sciences 3rd annual, 16 march 2015. [Online]. Available:
  8. 8.
    Petrou P, Vandoros S. Cyprus in crisis: recent changes in the pharmaceutical market and options for further reforms without sacrificing access to or quality of treatment. Health Policy. 2015;119(5):563–86.CrossRefPubMedGoogle Scholar
  9. 9.
    Joseph J, Solonos M, Michaelides M, et al. AB1093 Biosimilar infliximab in rheumatology practice—the Cyprus experience. Ann Rheum Dis. 76:2.Google Scholar
  10. 10.
    Egypt issues draft guidelines for biosimilars, Generics and Biosimilars Initiative Online, 2013.Google Scholar
  11. 11.
    Biosimilars, [Online]. Available:
  12. 12.
    Cheraghali AM. Biosimilars; a unique opportunity for Iran national health sector and national pharmaceutical industry. DARU J Pharm Sci. 2012;20:35.CrossRefGoogle Scholar
  13. 13.
    Development of Iranian guidelines for ‘biogenerics’. GaBI Online, Accessed date June 18, 2017.
  14. 14.
    Hadavand N.,Valadkhani M. and Zarbakhsh A. Current regulatory and scientific considerations for approving biosimilars in Iran. Egyptian journal of Medical Human Genetics, Elsevier, 27 Aug 2011.
  15. 15.
    Production of 24 biogeneric products in Iran by 2012, Generic and Biosimilar Initiative Online, 2012. [online]. Available:
  16. 16.
    Haddadin RD. Concept of biosimilar products in Jordan. Biological. 2011;39:333–5.CrossRefGoogle Scholar
  17. 17.
    Kasteng F.,Wilking N. and Jönsson B. Patient access to cancer drugs in nine countries in the Middle East. Semantic scholar. Accessed 1 June 2017.
  18. 18.•
    Republic of Lebanon Ministry of Public Health. 2015. [Online]. Available: Lebanon Accessed March 2, 2017. This PDF carries the guidelines of biosimilar use in Lebanon, one of the few countries to publish such guidance.
  19. 19.
  20. 20.
    Akcay E. Turkish approach to bringing biosimilars to market. Medical Regulatory Affairs Today, 2015.
  21. 21.
    Ministry Of Public Health Suoreme Council of Health, 2015. [Online]. Available:
  22. 22.•
    Ibrahim M.I.M.. Generic medicines policy in Qatar. Generic and Biosimilar Initiative Online 2015;4(1):8 This article gives short notes on the public health trends in Qatar, being one of the wealthiest countries in the region.
  23. 23.
    Guidelines on biosimilars., December 2010. [Online]. Available: Accessed 10 July 2017.
  24. 24.
    Lalichan, S. " How to market Generics and Biosimilars in Saudi Arabia". OMICS international, 18 Sept. 2015.
  25. 25.
    Abuelkhair M, Abdu S, Godman B, et al. Imperative to consider multiple initiatives to maximize prescribing efficiency from generic availability: case history from Abu Dhabi. Expert Rev Pharmacoecon Outcomes Res. 2012;12:115–24.CrossRefPubMedGoogle Scholar
  26. 26.
    Burki TK. Yemen’s hunger crisis. Lancet. 2012;380:637–8.CrossRefPubMedGoogle Scholar
  27. 27.
    Meleigy M. Yemen conflict takes its toll on civilians. Lancet. 2010;375:269–70.CrossRefPubMedGoogle Scholar
  28. 28.
    AL-Tamimi, Saleh Karamah, et al. “Challenges to Generic Medicines Utilization in Yemeni Healthcare System.” GaBI Journal, 27 Mar. 2013, Accessed 21 July 2017.
  29. 29.
    Counterfeit drugs: a growing global threat. Lancet 2012 Accessed 5 August 2017.

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2018

Authors and Affiliations

  • Nazar AbdulLateef Jassim
    • 1
  • Yasameen Abbas Humadi
    • 2
  1. 1.Rheumatology Unit, Department of Medicine, College of MedicineUniversity of BaghdadBaghdadIraq
  2. 2.Al-Nahrain College of MedicineBaghdadIraq

Personalised recommendations